Report Description

The global beyond the pill market is expected to show a robust growth with an impressive CAGR in the forecast years 2022-2026, on the account of increasing demands for effective healthcare system and effortless patient care. Healthcare industry is far beyond simple diagnosis and pharmaceutical treatment. Increasing demand for the fluid healthcare services that enhances the effects of the drugs and therapeutic procedures is anticipated to drive the growth of the global beyond the pill market in the upcoming five years.

Beyond the pill services by definition is a complete set of integrated products and services that is functional across the area of patient care meanwhile involving the patients, caregivers, and service providers, along with the pharmaceutical companies. These services are accompaniments to a pharmaceutical or therapeutic product that is utilized for the patient care and is also considered as a source of competitive advantages among the pharmaceutical and therapeutical global players. All three stakeholders physicians, regulators and payers, related to the customer experience influence the demand for the services and the market growth actively.

Digital Pharma Bridges Market Growth

Digitalization is acclimatizing the whole healthcare industry from past few decades. From drug-development, commercialization, to information & education aspect, digitalized pharmacology is expanding and driving the global beyond the pill market in the upcoming five years. Value added services like availability of monitoring devices, monitoring services, pharmaceutical management services, maintenance, education and information provision through online based services is influencing the growth of the global beyond the pill market in the next five years.

Digital pharma services or beyond the pill services act as a means to improve health outcomes that are anticipated from therapeutic or pharmaceutical product. These services are also enhancing the competition. Along with the rise in generics and biosimilars, competition among the global player is anticipated to accentuate and thus support the growth of the global beyond the pill market in the future five years.

Customer Demands Influence Market Growth

Customer orientation in beyond the pill market is more than just the patient but includes physicians, regulators, and payers. The customers are actively demanding for advancement in beyond the pill services. They seek effective services to deliver, track, measure the product and its services along with its impact on the health outcomes. Healthcare payers like health plan providers, investors, health insurance providers, etc. Moreover, economic and demographic pressure on the healthcare industry to satisfy the customer demands are forcing the pharmaceutical companies to improve their market performance and thus influencing the growth of the global beyond the pill market in the next five years.

Personalized Medicine Demand Drives Market Growth

Increasing demand and patient adherence toward personalized medicine drives the growth of the global beyond the pill market in the upcoming five years. Latest healthcare strategies include personalized therapeutics that biopharma companies are actively evolving and providing it for the patient care. The increased competition among the market players requires strategic approach to personalized medicine and therapeutics.

Also, with the added advantages of personalized medicine to diagnose and detect the disease in patient specific manner meanwhile categorizing the genetic variations and then extended provision of therapeutics and personalized medicine further enhance the growth prospects of the global beyond the pill market in the future five years.

Demand for Chronic Disease Management Supports Market Growth

Increasing instances of chronic diseases like cancer, neural diseases, cardiovascular diseases, etc. influences growth of healthcare sector in the recent times as well as in future. Expenses based on chronic diseases is influenced due to increasing cases too. More than 75% of healthcare expenses in the United States is on chronic diseases diagnosis and treatment. Treatment for such diseases require advanced tools and technologies that influences the standards of patient care in the global regions. Remote monitoring devices and services smart phone applications, and location based healthcare services includes the advancements and influences the future growth of the global beyond the pill market in the upcoming five years.


Click here to download the sample

Market Segmentation

The global beyond the pill market is segmented on the basis of therapeutic area, offerings, competitional landscape, and regional distribution. Based on therapeutic area, the market is further fragmented diabetes, oncology, cardiovascular diseases, asthma, and others. On the basis of offerings, the market is bifurcated into services, monitoring, assistance, information, and education. The market analysis also studies the regional segmentation to devise regional market segmentation, divided among Asia-Pacific region, North American region, European region, South American region, and Middle East & African region.

Company Profiles

F. Hoffmann-La Roche AG (Flatiron Health), Otsuka Pharmaceuticals Co., Ltd., Amgen, Inc., AstraZeneca Plc., Novartis AG, Sanofi S.A., Novo Nordisk A/S, Eli Lilly and Company, Johnson & Johnson, Teva Pharmaceutical Industries Ltd., are among the major market players in the global platform that lead the market growth of the global beyond the pill market.

Attribute

Details

Base Year

2020

Historical Data

2016 – 2019

Estimated Year

2021

Forecast Period

2022 – 2026

Quantitative Units

Revenue in USD Million, and CAGR for 2016-2020 and 2021-2026

Report coverage

Revenue forecast, company share, competitive landscape, growth factors, and trends

Segments covered

  • Therapeutic Area
  • Offerings

Regional scope

North America; Europe; Asia Pacific; South America; Middle East & Africa

Country scope

United States, Mexico, Canada, China, India, Japan, South Korea, Australia, Germany, France, United Kingdom, Spain, Italy, South Africa, UAE, Saudi Arabia, Kuwait, Brazil, Argentina, Colombia

Key companies profiled

F. Hoffmann-La Roche AG (Flatiron Health), Otsuka Pharmaceuticals Co., Ltd., Amgen, Inc., AstraZeneca Plc., Novartis AG, Sanofi S.A., Novo Nordisk A/S, Eli Lilly and Company, Johnson & Johnson, Teva Pharmaceutical Industries Ltd.,

Customization scope

10% free report customization with purchase. Addition or alteration to country, regional & segment scope.

Pricing and purchase options

Avail customized purchase options to meet your exact research needs. Explore purchase options

Delivery Format

PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)

 

Report Scope:

In this report, global beyond the pill market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

  • Beyond The Pill Market, By Therapeutic Area:
    • Diabetes
    • Oncology
    • Cardiovascular Diseases
    • Asthma
    • Others
  • Beyond The Pill Market, By Offerings:
    • Services
    • Monitoring
    • Assistance
    • Information
    • Education
  • Beyond the pill Market, By Region:
    • North America
      • United States
      • Mexico
      • Canada
    • Europe
      • France
      • Germany
      • United Kingdom
      • Italy
      • Spain
    • Asia-Pacific
      • China
      • India
      • Japan
      • South Korea
      • Australia
    • Middle East & Africa
      • South Africa
      • Saudi Arabia
      • UAE
      • Kuwait
    • South America
      • Brazil
      • Argentina
      • Colombia

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in global beyond the pill market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company’s specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).
Global Beyond The Pill Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]

Table of content

1.    Product Overview

2.    Research Methodology

3.    Impact of COVID-19 on Global Beyond the Pill Market

4.    Voice of Customer

4.1.  Brand Awareness

4.2.  Factors Contributing to switch over to Beyond the Pill

4.3.  Barriers to Adoption of Beyond the Pill

5.    Executive Summary

6.    Global Beyond the Pill Market Outlook

6.1.  Market Size & Forecast

6.1.1.     By Value

6.2.  Market Share & Forecast

6.2.1.     By Therapeutic Area (Diabetes, Oncology, Cardiovascular Diseases, Asthma, Others)

6.2.2.     By Offerings (Services, Monitoring, Assistance, Information, Education)

6.2.3.     By Company (2020)

6.2.4.     By Region

6.3.  Product Market Map

7.    North America Beyond the Pill Market Outlook

7.1.  Market Size & Forecast          

7.1.1.     By Value

7.2.  Market Share & Forecast

7.2.1.     By Therapeutic Area

7.2.2.     By Offerings

7.2.3.     By Country

7.3.  North America: Country Analysis

7.3.1.     United States Beyond the Pill Market Outlook

7.3.1.1.         Market Size & Forecast

7.3.1.1.1.             By Value

7.3.1.2.         Market Share & Forecast

7.3.1.2.1.             By Therapeutic Area

7.3.1.2.2.             By Offerings

7.3.2.     Mexico Beyond the Pill Market Outlook

7.3.2.1.         Market Size & Forecast

7.3.2.1.1.             By Value

7.3.2.2.         Market Share & Forecast

7.3.2.2.1.             By Therapeutic Area

7.3.2.2.2.             By Offerings

7.3.3.     Canada Beyond the Pill Market Outlook

7.3.3.1.         Market Size & Forecast

7.3.3.1.1.             By Value

7.3.3.2.         Market Share & Forecast

7.3.3.2.1.             By Therapeutic Area

7.3.3.2.2.             By Offerings

8.    Europe Beyond the Pill Market Outlook

8.1.  Market Size & Forecast          

8.1.1.     By Value

8.2.  Market Share & Forecast

8.2.1.     By Therapeutic Area

8.2.2.     By Offerings

8.2.3.     By Country

8.3.  Europe: Country Analysis

8.3.1.     France Beyond the Pill Market Outlook

8.3.1.1.         Market Size & Forecast

8.3.1.1.1.             By Value

8.3.1.2.         Market Share & Forecast

8.3.1.2.1.             By Therapeutic Area

8.3.1.2.2.             By Offerings

8.3.2.     Germany Beyond the Pill Market Outlook

8.3.2.1.         Market Size & Forecast

8.3.2.1.1.             By Value

8.3.2.2.         Market Share & Forecast

8.3.2.2.1.             By Therapeutic Area

8.3.2.2.2.             By Offerings

8.3.3.     United Kingdom Beyond the Pill Market Outlook

8.3.3.1.         Market Size & Forecast

8.3.3.1.1.             By Value

8.3.3.2.         Market Share & Forecast

8.3.3.2.1.             By Therapeutic Area

8.3.3.2.2.             By Offerings

8.3.4.     Italy Beyond the Pill Market Outlook

8.3.4.1.         Market Size & Forecast

8.3.4.1.1.             By Value

8.3.4.2.         Market Share & Forecast

8.3.4.2.1.             By Therapeutic Area

8.3.4.2.2.             By Offerings

8.3.5.     Spain Beyond the Pill Market Outlook

8.3.5.1.         Market Size & Forecast

8.3.5.1.1.             By Value

8.3.5.2.         Market Share & Forecast

8.3.5.2.1.             By Therapeutic Area

8.3.5.2.2.             By Offerings

9.    Asia-Pacific Beyond the Pill Market Outlook

9.1.  Market Size & Forecast          

9.1.1.     By Value

9.2.  Market Share & Forecast

9.2.1.     By Therapeutic Area

9.2.2.     By Offerings

9.2.3.     By Country

9.3.  Asia-Pacific: Country Analysis

9.3.1.     China Beyond the Pill Market Outlook

9.3.1.1.         Market Size & Forecast

9.3.1.1.1.             By Value

9.3.1.2.         Market Share & Forecast

9.3.1.2.1.             By Therapeutic Area

9.3.1.2.2.             By Offerings

9.3.2.     India Beyond the Pill Market Outlook

9.3.2.1.         Market Size & Forecast

9.3.2.1.1.             By Value

9.3.2.2.         Market Share & Forecast

9.3.2.2.1.             By Therapeutic Area

9.3.2.2.2.             By Offerings

9.3.3.     South Korea Beyond the Pill Market Outlook

9.3.3.1.         Market Size & Forecast

9.3.3.1.1.             By Value

9.3.3.2.         Market Share & Forecast

9.3.3.2.1.             By Therapeutic Area

9.3.3.2.2.             By Offerings

9.3.4.     Japan Beyond the Pill Market Outlook

9.3.4.1.         Market Size & Forecast

9.3.4.1.1.             By Value

9.3.4.2.         Market Share & Forecast

9.3.4.2.1.             By Therapeutic Area

9.3.4.2.2.             By Offerings

9.3.5.     Australia Beyond the Pill Market Outlook

9.3.5.1.         Market Size & Forecast

9.3.5.1.1.             By Value

9.3.5.2.         Market Share & Forecast

9.3.5.2.1.             By Therapeutic Area

9.3.5.2.2.             By Offerings

10.  South America Beyond the Pill Market Outlook

10.1.              Market Size & Forecast

10.1.1.  By Value

10.2.              Market Share & Forecast

10.2.1.  By Therapeutic Area

10.2.2.  By Offerings

10.2.3.  By Country

10.3.              South America: Country Analysis

10.3.1.  Brazil Beyond the Pill Market Outlook

10.3.1.1.      Market Size & Forecast

10.3.1.1.1.           By Value

10.3.1.2.      Market Share & Forecast

10.3.1.2.1.           By Therapeutic Area

10.3.1.2.2.           By Offerings

10.3.2.  Argentina Beyond the Pill Market Outlook

10.3.2.1.      Market Size & Forecast

10.3.2.1.1.           By Value

10.3.2.2.      Market Share & Forecast

10.3.2.2.1.           By Therapeutic Area

10.3.2.2.2.           By Offerings

10.3.3.  Colombia Beyond the Pill Market Outlook

10.3.3.1.      Market Size & Forecast

10.3.3.1.1.           By Value

10.3.3.2.      Market Share & Forecast

10.3.3.2.1.           By Therapeutic Area

10.3.3.2.2.           By Offerings

11.  Middle East and Africa Beyond the Pill Market Outlook

11.1.              Market Size & Forecast

11.1.1.  By Value

11.2.              Market Share & Forecast

11.2.1.  By Therapeutic Area

11.2.2.  By Offerings

11.2.3.  By Country

11.3.              MEA: Country Analysis

11.3.1.  South Africa Beyond the Pill Market Outlook

11.3.1.1.      Market Size & Forecast

11.3.1.1.1.           By Value

11.3.1.2.      Market Share & Forecast

11.3.1.2.1.           By Therapeutic Area

11.3.1.2.2.           By Offerings

11.3.2.  Saudi Arabia Beyond the Pill Market Outlook

11.3.2.1.      Market Size & Forecast

11.3.2.1.1.           By Value

11.3.2.2.      Market Share & Forecast

11.3.2.2.1.           By Therapeutic Area

11.3.2.2.2.           By Offerings

11.3.3.  UAE Beyond the Pill Market Outlook

11.3.3.1.      Market Size & Forecast

11.3.3.1.1.           By Value

11.3.3.2.      Market Share & Forecast

11.3.3.2.1.           By Therapeutic Area

11.3.3.2.2.           By Offerings

11.3.4.  Kuwait Beyond the Pill Market Outlook

11.3.4.1.      Market Size & Forecast

11.3.4.1.1.           By Value

11.3.4.2.      Market Share & Forecast

11.3.4.2.1.           By Therapeutic Area

11.3.4.2.2.           By Offerings

12.  Market Dynamics

12.1.              Drivers

12.2.              Challenges

13.  Market Trends & Developments

14.  Competitive Landscape

14.1.              F. Hoffmann-La Roche AG (Flatiron Health)

14.2.              Otsuka Pharmaceuticals Co., Ltd.

14.3.              Amgen, Inc.

14.4.              AstraZeneca Plc.

14.5.              Novartis AG

14.6.              Sanofi S.A.

14.7.              Novo Nordisk A/S

14.8.              Eli Lilly and Company

14.9.              Johnson & Johnson

14.10.            Teva Pharmaceutical Industries Ltd.

15.  Strategic Recommendations

16.  About Us & Disclaimer

Figures and Tables

Frequently asked questions

down-arrow

down-arrow

down-arrow

down-arrow

profile

Sakshi Bajaal

Business Consultant
Press Release

Beyond The Pill Market to Grow with Increasing Competition During the Forecast Period

Dec, 2021

Global healthcare system expansion is driving the growth in Global Beyond The Pill Market in the forecast period, 2022-2026.